Nucleon inc. had a competitive advantage over the competitors in pharmaceutical development technologies. Availability and exploitation of resources are based on high improved and advanced molecular biology and immunology. The competitors’ firms in the microbiology research in pharmaceutical enterprises were Elililly, Merck and Hoffman-LaRoche.
Presentations of values of Nucleon Inc. are on extensively doing research on CRP-1 molecule through studying genetic sequence. It has provided opportunities for the firm to become most competitive in pharmaceutical. The concern is on the development of technologies used in achieving the original results that helps in gaining patent right. The successes in research have helped the Nucleon Inc. to commercialize the technology through various strategies.
Availability of technology as a valuable and rare resource, it has enabled the Nucleon Inc. to become more successful in researches. It has provided the firm with a competitive advantage in advancing pharmaceutical technologies that have given other firms a challenge. It has presented Nucleon Inc. a position of leading and became a first mover. The value is contributed through the studies done on genetic hereditary through CRP-1 molecule and its impact on the pharmaceutical development.
Becoming imitable, the firm has accomplished and provided its channel and dependence path. It is expressed by improved technology in researches enabling it to accomplish the studies on the molecular biology. It has established the patent right and recognition through the researches on CRP-1 molecule despite challenges such as finances. Nucleon Inc. has a strong foundation making it have a great ground of licensing manufacturing rights to other pharmaceutical firms. The privileges that are available to Nucleon Inc. are based on capitalizing on patent position provided. Sustained competitive advantages for Nucleon Inc. firm are derived from variable, rare resources that are costly to imitate. Finally, other firms in pharmaceutical have to depend with the resources especially on advanced technology from Nucleon Inc. firm as they set their research development.
Bottom line note
Competitive advantages are as a result of technology improvement in researches. Pharmaceutical development has enabled Nucleon Inc. to capitalize on different strategies such as commercialization of new technologies.
